Labcorp Unveils H5 Bird Flu Testing Solution Confirmed for Use by Physicians in the U.S.

Labcorp Introduces H5 Bird Flu Test in the U.S.

Labcorp, a prominent global laboratory services provider, has announced the commercial launch of its new H5 bird flu molecular test, aimed at aiding the diagnosis of potential human infections caused by the H5N1 virus. This test is now available for physicians in the United States, allowing them to order it for patients who may have been exposed to the virus.

The introduction of this test comes during a multistate outbreak of H5 bird flu affecting poultry and dairy cows across various regions. While the immediate risk to the general public is considered low, health authorities, including the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Department of Agriculture (USDA), are closely monitoring the situation. Recently reported cases among dairy and poultry workers have prompted enhanced surveillance efforts.

Marcia Eisenberg, Ph.D., Labcorp's chief scientific officer, emphasized the significance of this launch, stating, "As we look to combat emerging infectious diseases, it's crucial that healthcare providers are equipped with the necessary diagnostic tools. Our collaboration with the CDC is designed to bolster public health preparedness by ensuring testing resources are readily available for assessment of H5 bird flu cases."

The H5 bird flu test utilizes polymerase chain reaction (PCR) methodology, utilizing a validated reagent tailored to detect the genetic material of the H5 virus. Healthcare practitioners can easily collect a nasopharyngeal swab specimen at the patient care location, which can then be sent to Labcorp for thorough analysis. Results are reported directly to both the healthcare provider and the patient.

Labcorp’s ongoing partnership with the CDC is part of a broader commitment to increasing testing capabilities for various emerging viruses that pose a risk to human health, including those responsible for Zika, COVID-19, and mpox.

For those interested in learning more about Labcorp’s H5 bird flu test, further information is available on their official site, with the caveat that it is not yet available in New York State.

Labcorp operates with the mission of enhancing health through its innovative laboratory services. Supporting over 67,000 clients in nearly 100 countries, they have played a vital role in bringing 84% of new drugs approved by the FDA in 2023 to market, demonstrating their extensive testing and diagnostic capabilities. Each year Labcorp processes more than 600 million tests for patients globally, ensuring they remain a leader in the field of laboratory diagnostics.

As the situation continues to evolve, Labcorp remains focused on strengthening the testing infrastructure, emphasizing its commitment to not just meet current health needs, but also to prepare for future challenges posed by infectious diseases.